Exxon Mobil Stock (XOM) Today: 2030 Plan Upgrade, Buyback Outlook and Analyst Forecasts as Oil Slips Below $60

Exxon Mobil Stock (XOM) Today: 2030 Plan Upgrade, Buyback Outlook and Analyst Forecasts as Oil Slips Below $60

Date: December 20, 2025 Exxon Mobil Corporation (NYSE: XOM) heads into the final stretch of 2025 with a familiar mix of forces shaping its share price: weakening crude prices, a heavy focus on low-cost production growth (especially the Permian Basin and Guyana), and investors’ ongoing appetite for dividends and buybacks. XOM last closed at $116.69 on Friday, December 19, 2025 (markets were closed Saturday), finishing slightly higher on the day after a choppy week of trading. StockAnalysis What’s new—and why it matters for Exxon stock right now—is that the company has raised its 2030 corporate plan targets while simultaneously leaning
Salesforce (CRM) Stock News and Forecasts on Dec. 20, 2025: Agentforce AI Momentum, Qualified Acquisition, and Wall Street Price Targets

Salesforce (CRM) Stock News and Forecasts on Dec. 20, 2025: Agentforce AI Momentum, Qualified Acquisition, and Wall Street Price Targets

December 20, 2025 — Salesforce, Inc. (NYSE: CRM) stock is heading into the final stretch of 2025 at the center of a debate investors know well: is this a beaten-down software leader becoming a bargain again, or a “value trap” in a market that’s rewarding AI infrastructure over traditional SaaS? MarketWatch On price action, Salesforce shares last traded around $259.91, after closing Friday, Dec. 19, 2025 at $259.91, up 0.80% on the day, with roughly 20.7 million shares traded. Investing.com What’s driving attention this weekend isn’t a single headline—it’s the convergence of AI commercialization, fresh M&A, and renewed analyst conviction
AppLovin (APP) Stock Update Dec. 20, 2025: Why Shares Are Surging, Fresh Analyst Targets, and the Next Catalysts

AppLovin (APP) Stock Update Dec. 20, 2025: Why Shares Are Surging, Fresh Analyst Targets, and the Next Catalysts

AppLovin Corporation (NASDAQ: APP) has become one of the market’s most closely watched adtech and AI-driven marketing stories—especially as investors debate how much runway remains in its e-commerce expansion and how durable its mobile gaming advertising strength will be into 2026. As of Dec. 20, 2025 (Saturday), U.S. markets are closed, so the most recent official close is Friday, Dec. 19. AppLovin stock finished that session at $721.37, up about 3.9% on the day, with after-hours trading around $725 in some feeds. MarketBeat+2Stock Analysis+2 Below is a comprehensive, publication-ready roundup of today’s key AppLovin stock news drivers, current forecasts and
CoreWeave (CRWV) Stock News and Forecasts for Dec. 20, 2025: DOE “Genesis Mission” Boosts Shares as Analysts Debate AI Data-Center Risks

CoreWeave (CRWV) Stock News and Forecasts for Dec. 20, 2025: DOE “Genesis Mission” Boosts Shares as Analysts Debate AI Data-Center Risks

CoreWeave, Inc. (NASDAQ: CRWV) ends the week back in the spotlight after a sharp Friday rebound that partially reversed a bruising late-2025 selloff. As of the Dec. 19, 2025 close (the last trading session ahead of Dec. 20), CoreWeave shares finished around $83, up roughly 22% on the day, according to MarketBeat’s end-of-day quote. MarketBeat The catalyst wasn’t a single headline—it was a “stack” of market-moving signals that hit within roughly 24–48 hours: That rebound arrives after weeks of volatile trading tied to a broader market debate: whether the AI infrastructure buildout is a durable, cash-generating megatrend—or the early innings
Lamb Weston (LW) Stock Plunges After Earnings Beat: Margin Pressure, 2026 Outlook, and Analyst Forecasts as of Dec. 20, 2025

Lamb Weston (LW) Stock Plunges After Earnings Beat: Margin Pressure, 2026 Outlook, and Analyst Forecasts as of Dec. 20, 2025

Lamb Weston Holdings, Inc. (NYSE: LW) is back in the market’s spotlight this weekend—and not because investors suddenly stopped liking French fries. After reporting second-quarter fiscal 2026 results that beat Wall Street expectations on revenue and adjusted earnings, Lamb Weston shares still fell sharply as investors zeroed in on what management said comes next: continued discounting, unfavorable price/mix, and higher international manufacturing costs that could keep profitability under pressure into the back half of the year. Barron’s+2Reuters+2 Below is what actually happened, what the company guided for fiscal 2026, and how analysts and market watchers are framing the bull case
Disc Medicine (NASDAQ: IRON) Stock Drops on FDA Voucher Speculation: Latest News, Analyst Forecasts, and What Investors Watch Next

Disc Medicine (NASDAQ: IRON) Stock Drops on FDA Voucher Speculation: Latest News, Analyst Forecasts, and What Investors Watch Next

Disc Medicine, Inc. (NASDAQ: IRON) stock is seeing a classic “biotech catalyst storm” on Dec. 20, 2025: big intraday swings, headline-driven volatility, and analysts arguing over whether the market is repricing risk or merely repricing uncertainty. As of the latest trading data available, IRON was around $80.04, down roughly 11.5% versus the prior close, after trading as high as $94.60 and as low as $71.46 on heavy volume (about 4.22 million shares). The immediate trigger: a report-driven debate about the FDA’s new fast-track voucher process and whether Disc’s lead drug candidate, bitopertin, remains on the clean, accelerated path bulls were
Intel Stock News Today (Dec. 20, 2025): Nvidia’s $5B Deal Clears, Intel Foundry Hits a Key 14A Milestone, and What Wall Street Forecasts for INTC

Intel Stock News Today (Dec. 20, 2025): Nvidia’s $5B Deal Clears, Intel Foundry Hits a Key 14A Milestone, and What Wall Street Forecasts for INTC

December 20, 2025 — Intel Corporation (NASDAQ: INTC) heads into the final stretch of 2025 with two narratives colliding: a high-profile partnership boost that removes a major regulatory overhang, and a “show-me” execution story that still hinges on foundry credibility, geopolitics, and earnings follow-through. As of the latest available quote early Saturday (UTC), Intel shares traded around $36.82, with heavy volume indicated versus typical sessions (noting that U.S. equity markets are closed on weekends and quotes can reflect delayed or off-session data). Below is what matters for Intel stock on 20.12.2025—the biggest headlines moving sentiment, the most-cited forecasts and price
Applied Digital Corporation Stock (APLD): Latest News, Earnings Outlook, Analyst Forecasts, and Key Risks as of Dec. 20, 2025

Applied Digital Corporation Stock (APLD): Latest News, Earnings Outlook, Analyst Forecasts, and Key Risks as of Dec. 20, 2025

Applied Digital Corporation (NASDAQ: APLD) is ending the week the way only an AI-infrastructure “picks-and-shovels” stock can: with a bruising selloff, a sharp rebound, and investors arguing about whether the company is building the future—or building a debt tower during an interest-rate era that does not forgive. On Friday, Dec. 19, APLD surged 16.53% to close at $27.85, after trading between $24.33 and $27.89 in the session, according to AAII’s recap. aaii.com That jump followed a volatile stretch where the market’s mood swung between “AI data centers are inevitable” and “okay, but who pays for all this concrete, copper, power,
Eli Lilly (LLY) Stock Outlook on Dec. 20, 2025: Orforglipron Pill Data, Price Cuts, and 2026 Forecasts Put the $1 Trillion Drugmaker Back in Focus

Eli Lilly (LLY) Stock Outlook on Dec. 20, 2025: Orforglipron Pill Data, Price Cuts, and 2026 Forecasts Put the $1 Trillion Drugmaker Back in Focus

Dec. 20, 2025 — Eli Lilly and Company (NYSE: LLY) is closing out 2025 with momentum—and with fresh headlines that underscore why Eli Lilly stock has become one of the market’s most closely watched healthcare names. Shares last closed at $1,071.44 (Dec. 19) after trading between $1,059.01 and $1,075.38, keeping the stock within reach of its recent highs. Stock Analysis The bigger story isn’t just the price. Lilly entered the rarefied “$1 trillion market value” club this year—an inflection point for a pharmaceutical company—and it’s doing so on the back of a rapidly expanding obesity and cardiometabolic franchise, a pipeline
BioMarin (BMRN) Stock Surges on $4.8B Amicus Deal: Latest News, Analyst Forecasts, and What to Watch Next (Dec. 20, 2025)

BioMarin (BMRN) Stock Surges on $4.8B Amicus Deal: Latest News, Analyst Forecasts, and What to Watch Next (Dec. 20, 2025)

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ended Friday’s session sharply higher after announcing a blockbuster rare-disease acquisition that immediately reframed the company’s growth story. Shares closed at $61.15, up about 17.7% on the day, with trading volume far above typical levels—classic “big-news repricing” behavior. Yahoo Finance The catalyst: BioMarin’s agreement to buy Amicus Therapeutics (NASDAQ: FOLD) for $14.50 per share in cash, valuing the deal at approximately $4.8 billion. BioMarin says the acquisition adds two marketed, growing therapies—Galafold (Fabry disease) and Pombiliti + Opfolda (Pompe disease)—plus U.S. rights to DMX-200 (a Phase 3 kidney-disease asset), while also resolving a key piece
Nike Stock (NKE) Slides After Fiscal Q2 2026 Earnings: Tariffs, China Weakness, Analyst Price Targets and the 2026 Outlook

Nike Stock (NKE) Slides After Fiscal Q2 2026 Earnings: Tariffs, China Weakness, Analyst Price Targets and the 2026 Outlook

Nike, Inc. (NYSE: NKE) is ending the week under intense investor scrutiny after a sharp post-earnings selloff reset expectations for the company’s turnaround. As of Dec. 20, 2025 (with U.S. markets closed for the weekend), Nike shares last closed at $58.71, down $6.92 (−10.54%) on unusually heavy volume, reflecting a market that’s increasingly focused on near-term margin pressure and China execution rather than a modest revenue beat. The move came after Nike reported fiscal second-quarter 2026 results (quarter ended Nov. 30, 2025) that topped profit expectations but highlighted three issues that continue to dominate the Nike stock narrative: tariff-driven cost
Carnival Corporation & plc Stock (NYSE: CCL) Jumps on Dividend Return, Record FY2025 Results, and a 2026 Outlook That Has Analysts Repricing the Cruise Giant

Carnival Corporation & plc Stock (NYSE: CCL) Jumps on Dividend Return, Record FY2025 Results, and a 2026 Outlook That Has Analysts Repricing the Cruise Giant

Carnival Corporation & plc stock is closing out 2025 with the kind of headline stack investors usually reserve for a comeback movie: record full‑year profit and revenue, investment‑grade leverage metrics, the first dividend in more than five years, and a proposal to simplify its unusual dual‑listed structure. The market’s initial reaction was loud—CCL finished Friday (Dec. 19) up about 9.8% at $31.12 after trading as high as $31.49, with volume north of 83 million shares. StockAnalysis This weekend’s coverage (Dec. 20, 2025) has focused on three big questions for anyone watching Carnival stock: Below is what’s new, what’s forecast, and

Stock Market Today

Anglo American share price slips as BofA turns neutral after copper outlook cut

Anglo American share price slips as BofA turns neutral after copper outlook cut

7 February 2026
Anglo American shares closed down 0.75% at 3,435 pence Friday after BofA Global Research downgraded the miner to “neutral” and raised its price target to 3,600 pence. Anglo cut its 2026 copper production guidance and warned of continued weakness at De Beers. The company expects $200 million in charges tied to its Chile copper operations in the second half of 2025.
Amazon’s $200B AI Spending Jolt Spurs Stock Selloff as Big Tech Capex Nears $650B

Amazon’s $200B AI Spending Jolt Spurs Stock Selloff as Big Tech Capex Nears $650B

7 February 2026
Amazon shares fell Friday after the company announced a $200 billion AI infrastructure plan for 2026, exceeding analyst expectations and reviving investor concerns about profitability. Combined 2026 capex flagged by Amazon, Alphabet, Microsoft, and Meta now tops $630 billion. Nvidia, AMD, and Broadcom shares surged on the news, while software and data firms remained under pressure.
Go toTop